Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis Pathobiology Subtitle: Pathological Myeloid Activation After Sepsis and Trauma
Who can join
Ages 18 to 100 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Sepsis participant: Inclusion Criteria: 1. age ≥18 years 2. meets criteria for sepsis/septic shock by Sepsis-3 consensus criteria. Exclusion Criteria: 1. have disease states that predispose to significant immune system dysfunction 2. have comorbidity burden or goals of care that preclude recovery after sepsis. These criteria include: a. irreversible shock (death \<12 hours) b. uncontrollable surgical source of sepsis c. patients deemed to be futile care or have advanced directives limiting resuscitative efforts d. alternative diagnoses causing shock state (e.g., hemorrhage, myocardial infarction or pulmonary embolus) e. known HIV infection with CD4+ count \<200 cells/mm3 g. severe traumatic brain injury with unencumbered assessment of GCS equaling 3 on admission to the intensive care unit. 3. known pregnancy 4. enrollment \>96 hours after suspected sepsis onset 5. pre-hospitalization bedridden performance status (WHO/Zubrod score ≥4) 6. subsequent clinical adjudication diagnosis not consistent with sepsis/septic shock by Sepsis-3 criteria. 7. Burn injury greater than 20% total body surface area (tBSA) Trauma Participant: Inclusion Criteria 1. All adults age ≥ 18 years 2. Blunt trauma patient with a. Injury Severity Score (ISS) greater than or equal to 25 b. ISS \> 15 and one of the following: i. \> 4 units of PRBC or \>3 units of whole blood or \>1500 ml of autogenous blood product in the first 24 hours of admission ii. AIS (acute injury score) \> 2 spine iii. Shock on arrival (Systolic blood pressure (SBP) \< 90) OR c. ISS \> 15 and two of the following: i. Age \> 55 ii. AIS \> 2 chest iii. +ETOH (ethyl alcohol) on arrival iv. Any red blood cell transfusion in first 24 hours Exclusion Criteria 1. Patients not expected to survive greater than 48 hours. 2. Prisoners. 3. Pregnancy. 4. Previous bone marrow transplantation. 5. Patients with End Stage Renal Disease. 6. Patients with any pre-existing hematological disease. 7. Patients deemed to be futile care or have advanced directives limiting resuscitative efforts. 8. Known HIV infection with CD4+ count \<200 cells/mm3 9. Burn injury greater than 20% tBSA
About the study
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
What is being tested
- Blood sampling (other)
Sponsor: University of Florida · Participants: 450 · Started: Jan 4, 2022
Contact the study team
- Jennifer Lanz, MSN · Phone: 352-273-5497
- Ruth Davis, BSN · Phone: 352-273-5897
Official record on ClinicalTrials.gov — NCT05110937
Locations in the U.S.
| Florida | UF Health at Shands hospital, Gainesville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.